Last reviewed · How we verify
ALTB-268
ALTB-268 is a small molecule inhibitor of the CD47/SIRPα axis.
ALTB-268 is a small molecule inhibitor of the CD47/SIRPα axis. Used for Relapsed or refractory multiple myeloma.
At a glance
| Generic name | ALTB-268 |
|---|---|
| Sponsor | AltruBio Inc. |
| Drug class | CD47/SIRPα axis inhibitor |
| Target | CD47/SIRPα axis |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By blocking the interaction between CD47 and SIRPα, ALTB-268 aims to prevent tumor cells from evading immune surveillance. This mechanism is thought to enhance the body's immune response against cancer cells.
Approved indications
- Relapsed or refractory multiple myeloma
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Vomiting
- Anemia
- Thrombocytopenia
- Neutropenia
- Leukopenia
- Anorexia
- Weight loss
Key clinical trials
- Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants (PHASE1)
- Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics (PHASE2)
- A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALTB-268 CI brief — competitive landscape report
- ALTB-268 updates RSS · CI watch RSS
- AltruBio Inc. portfolio CI